EDIT Earnings & Financial Statements
Editas Medicine, Inc.
$2.83
+$0.08(+2.73%)
46
Overall
55
Value
45
Tech
39
Quality
Market Cap
$422.35M
Volume
4.04M
52W Range
$1.66 - $4.54
Target Price
$5.68
EDIT earnings and financial statements: Editas Medicine, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
EDIT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $40.52M | $32.31M | $78.12M | $19.71M | $25.54M |
| Operating income | -$160.01M | -$251.15M | -$169.18M | -$225.95M | -$193.15M |
| EBITDA | -$148.63M | -$229.11M | -$147.12M | -$214.13M | -$188.09M |
| Net income | -$160.10M | -$237.10M | -$153.22M | -$220.43M | -$192.50M |
| EPS (diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.83 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $186.53M | $341.59M | $499.15M | $514.32M | $677.48M |
| Total liabilities | $159.25M | $207.31M | $150.06M | $153.64M | $123.84M |
| Shareholders’ equity | $27.29M | $134.27M | $349.10M | $360.68M | $553.64M |
| Cash and equivalents | $146.65M | $131.54M | $123.65M | $141.52M | $203.52M |
| Long-term debt | $65.68M | $72.81M | $24.37M | $32.86M | $16.07M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$165.24M | -$210.28M | -$132.18M | -$177.35M | -$163.80M |
| Capital expenditure | -$338.0K | -$8.83M | -$4.72M | -$4.12M | -$7.98M |
| Free cash flow | -$165.85M | -$219.11M | -$136.90M | -$181.47M | -$171.78M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EDIT | $2.83 | +2.7% | 4.04M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |